CD19 and B-cell non-Hodgkin lymphoma: CAR(NAP)-T cells targeting CD20 have the potential to treat B cell lymphomas irrespective of prior CD19 CAR-T cell therapy and may prevent subsequent CAR-antigen-negative relapses.